Jun 2026 (Q2 FY26) — Aug 6, 2026
Puma Biotechnology Q2 FY26 — Strong NERLYNX Sales and Positive Net Income Guidance
Read the full callPuma Biotechnology (PBYI) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Puma Biotechnology earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 56.5 | +7.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 13.4 | +0.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 8.2 | +39.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$10.21 +3.87% · +$0.38
Performance +86.7% 1Y
1Y: $5.47 on 17 Oct 2025 → $10.21. High $10.52 (15 Oct 2026), low $4.73 (10 Nov 2025).
- Previous close
- $9.83
- 52-week range
- $4.73 – $10.52
- One year
- +87.34%
Overview
- Symbol
- PBYI
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Puma Biotechnology earnings calls (PBYI)
Financials
What the filings say
Net profit, year on year: +40% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 81 | 59 | 46 | 52 | 54 | 75 | 45 | 57 |
| Expenses | 58 | 46 | 42 | 46 | 45 | 58 | 49 | 49 |
| Operating profit | 22 | 13 | 4 | 7 | 10 | 17 | -4 | 8 |
| Operating margin | 27.4% | 22.6% | 8.7% | 12.7% | 17.6% | 22.7% | −8.5% | 13.4% |
| Other income | -1 | -1 | -1 | -0 | -0 | 0 | 0 | 1 |
| Interest | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 0 |
| Profit before tax | 21 | 12 | 3 | 6 | 9 | 17 | -3 | 8 |
| Tax rate | 1.4% | −57.8% | — | — | — | — | — | — |
| Net profit | 20 | 19 | 3 | 6 | 9 | 13 | -4 | 8 |
| EPS ($ per share) | 0.41 | — | 0.06 | 0.12 | 0.18 | — | -0.07 | 0.16 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -1,202 | -1,278 | -1,338 | -1,367 | -1,367 | -1,345 | -1,315 | -1,284 |
| Total liabilities | 225 | 217 | 250 | 229 | 200 | 177 | 121 | 86 |
| Fixed assets | 4 | 3 | 2 | 2 | 1 | 1 | 1 | 0 |
| Investments | 57 | 52 | 8 | 19 | 5 | 11 | 32 | 68 |
| Total assets | 259 | 235 | 244 | 227 | 222 | 231 | 213 | 216 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24 | 22 | 1 | 21 | -16 | 27 | 39 | 42 |
| Cash from investing | -58 | 5 | 33 | -11 | 7 | -19 | -20 | -36 |
| Cash from financing | 108 | -67 | -10 | -32 | 12 | 0 | -34 | -45 |
| Net cash flow | 27 | -40 | 24 | -22 | 4 | 8 | -15 | -40 |
| Capital expenditure | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 |
| Free cash flow | -25 | 22 | 1 | 21 | -16 | 27 | 39 | 42 |
Insider filings
28 filings between Nov 11, 2025 and Sep 14, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.12M
17 sales by 10 insiders
94% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 10
- Award — granted as compensation
- 1
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| AUERBACH ALAN H | — | $568.9K | Jul 6, 2026 |
| Cesano Alessandra | — | $567.0K | Sep 14, 2026 |
| Senderowicz Adrian | — | $194.3K | Jun 12, 2026 |
| MOYES JAY M | — | $158.8K | Jun 12, 2026 |
| NOUGUES MAXIMO F | — | $141.7K | Jul 6, 2026 |
| WILSON TROY EDWARD | — | $123.2K | Sep 14, 2026 |
| HUNT DOUGLAS M | — | $122.6K | Jul 6, 2026 |
| MILLER MICHAEL PATRICK | — | $97.2K | Nov 11, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Cesano Alessandra Director | Option exercise 10b5-1 plan | 50,000 | $146.5K |
| Sep 14, 2026 | WILSON TROY EDWARD Director | Sale 10b5-1 plan | 5,000 | $45.5K |
| Sep 14, 2026 | Cesano Alessandra Director | Sale 10b5-1 plan | 62,150 | $567.0K |
| Jul 6, 2026 | AUERBACH ALAN H President and CEO | Sale 10b5-1 plan | 44,058 | $364.1K |
| Jul 6, 2026 | NOUGUES MAXIMO F Chief Financial Officer | Sale 10b5-1 plan | 9,386 | $77.6K |
| Jul 6, 2026 | HUNT DOUGLAS M See Remarks | Sale 10b5-1 plan | 8,460 | $69.9K |
| Jun 12, 2026 | Dorval Allison Director | Sale 10b5-1 plan | 11,610 | $83.6K |
| Jun 12, 2026 | MOYES JAY M Director | Sale 10b5-1 plan | 22,000 | $158.8K |
| Jun 12, 2026 | Senderowicz Adrian Director | Sale 10b5-1 plan | 27,000 | $194.3K |
| Jun 12, 2026 | Stuglik Brian M Director | Sale 10b5-1 plan | 8,100 | $58.3K |
| Jun 12, 2026 | WILSON TROY EDWARD Director | Sale 10b5-1 plan | 10,800 | $77.7K |
| Jun 11, 2026 | Stuglik Brian M Director | Award 10b5-1 plan | 27,000 | $0 |
| Jun 11, 2026 | Cesano Alessandra Director | Award | 27,000 | $0 |
| Jun 11, 2026 | WILSON TROY EDWARD Director | Award 10b5-1 plan | 27,000 | $0 |
| Jun 11, 2026 | MOYES JAY M Director | Award 10b5-1 plan | 27,000 | $0 |
| Jun 11, 2026 | Senderowicz Adrian Director | Award 10b5-1 plan | 27,000 | $0 |
| Jun 11, 2026 | MILLER MICHAEL PATRICK Director | Award | 27,000 | $0 |
| Jun 11, 2026 | Dorval Allison Director | Award 10b5-1 plan | 27,000 | $0 |
| Feb 18, 2026 | HUNT DOUGLAS M See Remarks | Award | 49,394 | $0 |
| Feb 18, 2026 | NOUGUES MAXIMO F Chief Financial Officer | Award | 46,739 | $0 |
| Feb 18, 2026 | AUERBACH ALAN H President and CEO | Award | 159,778 | $0 |
| Jan 7, 2026 | NOUGUES MAXIMO F Chief Financial Officer | Sale 10b5-1 plan | 6,405 | $37.7K |
| Jan 7, 2026 | HUNT DOUGLAS M See Remarks | Sale 10b5-1 plan | 5,014 | $29.5K |
| Jan 7, 2026 | AUERBACH ALAN H President and CEO | Sale 10b5-1 plan | 18,012 | $105.9K |
| Jan 6, 2026 | HUNT DOUGLAS M See Remarks | Sale 10b5-1 plan | 3,973 | $23.2K |
| Jan 6, 2026 | AUERBACH ALAN H President and CEO | Sale 10b5-1 plan | 16,938 | $99.0K |
| Jan 6, 2026 | NOUGUES MAXIMO F Chief Financial Officer | Sale 10b5-1 plan | 4,540 | $26.5K |
| Nov 11, 2025 | MILLER MICHAEL PATRICK Director | Sale | 20,000 | $97.2K |
| Jul 18, 2025 | Cesano Alessandra Director | Sale 10b5-1 plan | 27,000 | $90.9K |
| Jul 9, 2025 | AUERBACH ALAN H President and CEO | Sale 10b5-1 plan | 21,580 | $76.3K |
| Jul 9, 2025 | HUNT DOUGLAS M See Remarks | Sale 10b5-1 plan | 3,443 | $12.2K |
| Jul 9, 2025 | NOUGUES MAXIMO F Chief Financial Officer | Sale 10b5-1 plan | 3,935 | $13.9K |
| Jul 8, 2025 | HUNT DOUGLAS M See Remarks | Sale 10b5-1 plan | 4,374 | $15.5K |
| Jul 8, 2025 | AUERBACH ALAN H President and CEO | Sale 10b5-1 plan | 25,592 | $90.4K |
| Jul 8, 2025 | NOUGUES MAXIMO F Chief Financial Officer | Sale 10b5-1 plan | 5,587 | $19.7K |
| Jun 13, 2025 | Senderowicz Adrian Director | Sale 10b5-1 plan | 27,000 | $91.8K |
| Jun 13, 2025 | Stuglik Brian M Director | Sale 10b5-1 plan | 8,100 | $27.5K |
| Jun 13, 2025 | WILSON TROY EDWARD Director | Sale 10b5-1 plan | 10,800 | $36.7K |
| Jun 13, 2025 | MOYES JAY M Director | Sale 10b5-1 plan | 22,000 | $74.8K |
| Jun 13, 2025 | Dorval Allison Director | Sale 10b5-1 plan | 11,610 | $39.5K |
| Jun 13, 2025 | Cesano Alessandra Director | Sale 10b5-1 plan | 12,150 | $41.3K |
| Jun 11, 2025 | Dorval Allison Director | Award | 27,000 | $0 |
| Jun 11, 2025 | MOYES JAY M Director | Award | 27,000 | $0 |
| Jun 11, 2025 | Senderowicz Adrian Director | Award | 27,000 | $0 |
| Jun 11, 2025 | MILLER MICHAEL PATRICK Director | Award | 27,000 | $0 |
| Jun 11, 2025 | Cesano Alessandra Director | Award | 27,000 | $0 |
| Jun 11, 2025 | WILSON TROY EDWARD Director | Award | 27,000 | $0 |
| Jun 11, 2025 | Stuglik Brian M Director | Award | 27,000 | $0 |
| Feb 7, 2025 | NOUGUES MAXIMO F Chief Financial Officer | Award | 61,456 | $0 |
| Feb 7, 2025 | AUERBACH ALAN H President and CEO | Award | 198,399 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for PUMA BIOTECHNOLOGY, INC.
Free account. Everything above stays public.
Write why you follow PUMA BIOTECHNOLOGY, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading